As of May 22
| -0.17 / -1.05%|
The 3 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 27.50, with a high estimate of 30.00 and a low estimate of 23.00. The median estimate represents a +71.87% increase from the last price of 16.00.
The current consensus among 3 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.